Business
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience\nTORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\" or the \"Company\") a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S. President Donald Trump’s executive order  to expedite the reclassification of cannabis under the U.S. Controlled Substances Act from Schedule I to Schedule III (the \"Order\").1 This change recognizes the medical use of cannabis and reduces barriers to research. MediPharm Labs is well positioned to benefit from this milestone through its FDA site registration, Drug Establishment License (\"DEL\") and proven experience supplying clinical trial materials to the United States. \"This reclassification order is a historic milestone that validates MediPharm's pharmaceutical approach and one that we anticipate will strengthen our ability to expand U.S. clinical trial partnerships,\" said David Pidduck, Chief Executive Officer of MediPharm Labs. \"This change could facilitate significant growth in clinical research, and MediPharm is uniquely prepared to support clinical trial partners and patients. We have already shipped product for U.S. trials, a capability that others may take years to achieve.\" Rescheduling will Accelerate Cannabis Clinical Research \"This reclassification order will make it far easier to conduct marijuana-related medical research, allowing us to study benefits, potential dangers and future treatments,\" U.S. President Trump said in the Oval Office. \"It's going to have a tremendously positive impact.\" 2 Reclassifying cannabis to Schedule III recognizes its medical use and will remove barriers that have long limited U.S. clinical trials. Researchers publish thousands of peer-reviewed cannabis studies annually, yet full clinical trials remain scarce due to Schedule I restrictions and lack of federally compliant cannabis. The FDA has also received more than 800 Investigational New Drug applications for cannabis-derived and cannabis-related products.3 Rescheduling is expected to accelerate research by enabling access to standardized medical-grade cannabis from registered suppliers. For...